nach oben

NeuroMolecular Medicine

Erschienen in:

15.02.2018 | Original Paper

Differential Binding of Human ApoE Isoforms to Insulin Receptor is Associated with Aberrant Insulin Signaling in AD Brain Samples

verfasst von: Elizabeth S. Chan, Christopher Chen, Tuck Wah Soong, Boon-Seng Wong

Erschienen in: NeuroMolecular Medicine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Apolipoprotein E4 (ApoE4) is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD), where inheritance of this isoform predisposes development of AD in a gene dose-dependent manner. Although the mode of action of ApoE4 on AD onset and progression remains unknown, we have previously shown that ApoE4, and not ApoE3 expression, resulted in insulin signaling deficits in the presence of amyloid beta (Aβ). However, these reports were not conducted with clinical samples that more accurately reflect human disease. In this study, we investigated the effect of ApoE genotype on the insulin signaling pathway in control and AD human brain samples. We found that targets of the insulin signaling pathway were attenuated in AD cases, regardless of ApoE isoform. We also found a decrease in GluR1 subunit expression, and an increase NR2B subunit expression in AD cases, regardless of ApoE isoform. Lastly, we observed that more insulin receptor (IR) was immunoprecipitated in control cases, and more Aβ was immunoprecipitated with AD cases. But, when comparing among AD cases, we found that more IR was immunoprecipitated with ApoE3 than ApoE4, and more Aβ was immunoprecipitated with ApoE4 than ApoE3. Our results suggest that the difference in IR binding and effect on protein expression downstream of the IR may affect onset and progression of AD.

Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., et al. (2009). Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. Journal of Neuroscience, 29, 6771–6779.CrossRefPubMed

Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences USA, 96, 15233–15238.CrossRef

Beffert, U., & Poirier, J. (1998). ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation. NeuroReport, 9, 3321–3323.CrossRefPubMed

Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Wang, C., & Huang, Y. (2011). C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice. Proceedings of the National Academy of Sciences USA, 108, 4236–4241.CrossRef

Bien-Ly, N., Gillespie, A. K., Walker, D., Yoon, S. Y., & Huang, Y. (2012). Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. Journal of Neuroscience, 32, 4803–4811.CrossRefPubMedPubMedCentral

Bomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J. C., Decker, H., et al. (2012). An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease—associated Abeta oligomers. The Journal of Clinical Investigation, 122, 1339–1353.CrossRefPubMedPubMedCentral

Chan, E. S., Chan, C., Cole, G. M., & Wong, B. S. (2015). Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic mice. Scientific Reports, 5, 13842.CrossRefPubMedPubMedCentral

Chan, E. S., Shetty, M. S., Sajikumar, S., Chen, C., Soong, T. W., & Wong, B.-S. (2016). ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Aβ impairment of insulin signaling in an Alzheimer’s disease mouse model. Scientific Reports, 6, 26119.CrossRefPubMedPubMedCentral

Chua, L. M., Lim, M. L., Chong, P. R., Hu, Z. P., Cheung, N. S., & Wong, B. S. (2012). Impaired neuronal insulin signaling precedes A beta(42) accumulation in female A beta PPsw/PS1 Delta E9 Mice. Journal of Alzheimer’s Disease, 29, 783–791.PubMed

Cole, G. M., & Frautschy, S. A. (2007). The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s disease. Experimental Gerontology, 42, 10–21.CrossRefPubMed

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261, 921–923.CrossRefPubMed

Correia, S. C., Santos, R. X., Perry, G., Zhu, X., Moreira, P. I., & Smith, M. A. (2011). Insulin-resistant brain state: The culprit in sporadic Alzheimer’s disease? Ageing Research Reviews, 10, 264–273.CrossRefPubMedPubMedCentral

Craft, S., Asthana, S., Cook, D. G., Baker, L. D., Cherrier, M., Purganan, K., et al. (2003). Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: Interactions with apolipoprotein E genotype. Psychoneuroendocrinology, 28, 809–822.CrossRefPubMed

Craft, S., Baker, L. D., Montine, T. J., Minoshima, S., Watson, G. S., Claxton, A., et al. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Archives of Neurology, 69, 29–38.CrossRefPubMed

Craft, S., & Watson, G. S. (2004). Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurology, 3, 169–178.CrossRefPubMed

Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y., Karlo, J. C., Zinn, A. E., et al. (2012). ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science, 335, 1503–1506.CrossRefPubMedPubMedCentral

De Felice, F. G., Vieira, M. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., et al. (2009). Protection of synapses against Alzheimer’s-linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proceedings of the National Academy of Sciences USA, 106, 1971–1976.CrossRef

de la Monte, S. M. (2009). Insulin resistance and Alzheimer’s disease. BMB Reports, 42, 475–481.CrossRefPubMedPubMedCentral

Decker, H., Lo, K. Y., Unger, S. M., Ferreira, S. T., & Silverman, M. A. (2010). Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. Journal of Neuroscience, 30, 9166–9171.CrossRefPubMed

Frolich, L., Blum-Degen, D., Bernstein, H. G., Engelsberger, S., Humrich, J., Laufer, S., et al. (1998). Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. Journal of Neural Transmission, 105, 423–438.CrossRefPubMed

Garai, K., Verghese, P. B., Baban, B., Holtzman, D. M., & Frieden, C. (2014). The binding of apolipoprotein E to oligomers and fibrils of amyloid-beta alters the kinetics of amyloid aggregation. Biochemistry, 53, 6323–6331.CrossRefPubMedPubMedCentral

Gual, P., Le Marchand-Brustel, Y., & Tanti, J. F. (2005). Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie, 87, 99–109.CrossRefPubMed

Hardingham, G. E., & Bading, H. (2003). The Yin and Yang of NMDA receptor signalling. Trends in Neurosciences, 26, 81–89.CrossRefPubMed

Hayashi, Y., Shi, S. H., Esteban, J. A., Piccini, A., Poncer, J. C., & Malinow, R. (2000). Driving AMPA receptors into synapses by LTP and CaMKII: Requirement for GluR1 and PDZ domain interaction. Science, 287, 2262–2267.CrossRefPubMed

Hemmings, B. A., & Restuccia, D. F. (2012). PI3K-PKB/Akt pathway. Cold Spring Harbor Perspectives in Biology, 4, a011189.CrossRefPubMedPubMedCentral

Holscher, C. (2014). First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 10, S33–S37.CrossRef

Hoyer, S. (2002). The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. Journal Of Neural Transmission, 109, 991–1002.CrossRefPubMed

Huang, Y., & Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell, 148, 1204–1222.CrossRefPubMedPubMedCentral

Huynh, T.-P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., et al. (2017). Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of β-amyloidosis. Neuron, 96(1013–1023), e1014.

Lacor, P. N., Buniel, M. C., Furlow, P. W., Clemente, A. S., Velasco, P. T., Wood, M., et al. (2007). Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. Journal of Neuroscience, 27, 796–807.CrossRefPubMed

LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., & Frail, D. E. (1994). Isoform-specific binding of apolipoprotein E to beta-amyloid. Journal of Biological Chemistry, 269, 23403–23406.PubMed

Lee, C. C., Kuo, Y. M., Huang, C. C., & Hsu, K. S. (2009). Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiology of Aging, 30, 377–387.CrossRefPubMed

Li, M., Zhang, D. Q., Wang, X. Z., & Xu, T. J. (2011). NR2B-containing NMDA receptors promote neural progenitor cell proliferation through CaMKIV/CREB pathway. Biochemical and Biophysical Research Communications, 411, 667–672.CrossRefPubMed

Liu, C.-C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C.-W., et al. (2017). ApoE4 accelerates early seeding of amyloid pathology. Neuron, 96(1024–1032), e1023.

Liu, Z., Zhao, W., Xu, T., Pei, D., & Peng, Y. (2010). Alterations of NMDA receptor subunits NR1, NR2A and NR2B mRNA expression and their relationship to apoptosis following transient forebrain ischemia. Brain Research, 1361, 133–139.CrossRefPubMed

Mahley, R. W., & Huang, Y. (2012). Apolipoprotein e sets the stage: Response to injury triggers neuropathology. Neuron, 76, 871–885.CrossRefPubMedPubMedCentral

Malinow, R., & Malenka, R. C. (2002). AMPA receptor trafficking and synaptic plasticity. Annual Review of Neuroscience, 25, 103–126.CrossRefPubMed

Manning, B. D., & Cantley, L. C. (2007). AKT/PKB signaling: Navigating downstream. Cell, 129, 1261–1274.CrossRefPubMedPubMedCentral

Myers, M. G., Jr., Grammer, T. C., Wang, L. M., Sun, X. J., Pierce, J. H., Blenis, J., et al. (1994). Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. Journal of Biological Chemistry, 269, 28783–28789.PubMed

Nistico, R., Cavallucci, V., Piccinin, S., Macri, S., Pignatelli, M., Mehdawy, B., et al. (2012). Insulin receptor beta-subunit haploinsufficiency impairs hippocampal late-phase LTP and recognition memory. Neuromolecular Medicine, 14, 262–269.CrossRefPubMed

Ong, Q. R., Chan, E. S., Lim, M. L., Cole, G. M., & Wong, B. S. (2014). Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Sci Rep, 4, 3754.CrossRefPubMedPubMedCentral

Palop, J. J., & Mucke, L. (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: From synapses toward neural networks. Nature Neuroscience, 13, 812–818.CrossRefPubMedPubMedCentral

Roselli, F., Tirard, M., Lu, J., Hutzler, P., Lamberti, P., Livrea, P., et al. (2005). Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. Journal of Neuroscience, 25, 11061–11070.CrossRefPubMed

Sanan, D. A., Weisgraber, K. H., Russell, S. J., Mahley, R. W., Huang, D., Saunders, A., et al. (1994). Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. The Journal of Clinical Investigation, 94, 860–869.CrossRefPubMedPubMedCentral

Selkoe, D. J. (2011). Alzheimer’s disease. Cold Spring Harbor Perspectives in Biology, 3, 7.CrossRef

Tai, L. M., Bilousova, T., Jungbauer, L., Roeske, S. K., Youmans, K. L., Yu, C., et al. (2013). Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. Journal of Biological Chemistry, 288, 5914–5926.CrossRefPubMedPubMedCentral

Tai, L. M., Koster, K. P., Luo, J., Lee, S. H., Wang, Y. T., Collins, N. C., et al. (2014). Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. Journal of Biological Chemistry, 289, 30538–30555.CrossRefPubMedPubMedCentral

Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., et al. (2012). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. Journal of Clinical Investigation, 122, 1316–1338.CrossRefPubMedPubMedCentral

Townsend, M., Mehta, T., & Selkoe, D. J. (2007). Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. Journal of Biological Chemistry, 282, 33305–33312.CrossRefPubMed

Verdier, Y., Zarandi, M., & Penke, B. (2004). Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer’s disease. Journal of Peptide Science, 10, 229–248.CrossRefPubMed

Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011). Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurology, 10, 241–252.CrossRefPubMedPubMedCentral

Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., Van Bronswijk, W., & Martins, R. (2002). Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor. The Journal of Neuroscience, 22, RC221.PubMed

Zhao, W. Q., & Alkon, D. L. (2001). Role of insulin and insulin receptor in learning and memory. Molecular and Cellular Endocrinology, 177, 125–134.CrossRefPubMed

Zhao, W. Q., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., et al. (2008). Amyloid beta oligomers induce impairment of neuronal insulin receptors. The FASEB Journal, 22, 246–260.CrossRefPubMed

Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., et al. (2017). Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron, 96(115–129), e115.CrossRef

Zhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., et al. (2004). Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer’s disease intervention. Journal of Neuroscience, 24, 11120–11126.CrossRefPubMed

Titel: Differential Binding of Human ApoE Isoforms to Insulin Receptor is Associated with Aberrant Insulin Signaling in AD Brain Samples
verfasst von: Elizabeth S. Chan
Christopher Chen
Tuck Wah Soong
Boon-Seng Wong
Publikationsdatum: 15.02.2018
Verlag: Springer US
Erschienen in: NeuroMolecular Medicine / Ausgabe 1/2018
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-018-8480-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Differential Binding of Human ApoE Isoforms to Insulin Receptor is Associated with Aberrant Insulin Signaling in AD Brain Samples

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Correction of Huntington’s Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model

Combination Therapy with Low-Dose IVIG and a C1-esterase Inhibitor Ameliorates Brain Damage and Functional Deficits in Experimental Ischemic Stroke

Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies

Vitamin D3 Supplementation Reduces Subsequent Brain Injury and Inflammation Associated with Ischemic Stroke

Molecular Insights into the Roles of Rab Proteins in Intracellular Dynamics and Neurodegenerative Diseases

Serum Mortalin Correlated with α-Synuclein as Serum Markers in Parkinson’s Disease: A Pilot Study

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie